T1	Participants 74 119	autosomal dominant polycystic kidney disease.
T2	Participants 131 183	Autosomal dominant polycystic kidney disease (ADPKD)
T3	Participants 213 255	end-stage kidney failure in most patients.
T4	Participants 575 595	patients with ADPKD.
T5	Participants 596 714	Sixty patients were initially recruited but 49 of these received either pravastatin 20 mg or no treatment for 2 years.
